Previous Close | 12.80 |
Open | 12.59 |
Bid | 9.27 x 200 |
Ask | 15.94 x 200 |
Day's Range | 12.37 - 12.90 |
52 Week Range | 5.55 - 15.90 |
Volume | |
Avg. Volume | 410,119 |
Market Cap | 561.106M |
Beta (5Y Monthly) | 1.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.33 |
Earnings Date | Nov 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 27, 2010 |
1y Target Est | 17.83 |
Axogen ( NASDAQ:AXGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$48.6m (up 18% from 3Q 2023). Net...
AxoGen ( (AXGN) ) just unveiled an update. Axogen, Inc., a leader in peripheral nerve repair solutions, reported a notable 17.9% revenue increase for Q3 2024 at $48.6 million, alongside a decrease in net loss to $1.9 million from $4.1 million in the previous year. The company’s strategic advancements include FDA acceptance of its Biologics License Application for Avance Nerve Graft and promising engagement at industry events. Axogen aims to hit the high end of its revenue and gross margin guidan